Certolizumab pegol
Syringe with 200mg Certolizumab pegol | |
| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Humanized (from mouse) |
| Target | TNF alpha |
| Clinical data | |
| Trade names | Cimzia |
| Other names | CDP870 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608041 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | about 11 days |
| Excretion | Kidney (PEG only) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2115H3252N556O673S16 |
| Molar mass | 47749.46 g·mol−1 |
| (what is this?) (verify) | |
Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[3][4] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.[5][6][1]
It is on the World Health Organization's List of Essential Medicines.[7]
- ^ a b "Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution". DailyMed. April 24, 2020. Retrieved July 18, 2020.
- ^ Cite error: The named reference
Cimzia EPARwas invoked but never defined (see the help page). - ^ Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". The New England Journal of Medicine. 357 (3): 228–238. doi:10.1056/NEJMoa067594. PMID 17634458.
{{cite journal}}: CS1 maint: overridden setting (link) - ^ Goel N, Stephens S (2010). "Certolizumab pegol". mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560.
- ^ Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert Opinion on Biological Therapy. 5 (4): 601–606. doi:10.1517/14712598.5.4.601. PMID 15934837. S2CID 21974683.
- ^ "Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160". U.S. Food and Drug Administration (FDA). December 24, 1999. Archived from the original on February 15, 2015. Retrieved July 18, 2020.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.